Expertise in

conditions

Pier L. Zinzani

Bologna, IT

Clinical Trials:Currently Recruiting for 1 Trial

Expertise in

conditions

Bologna, IT

Overview

Pier Zinzani practices practicing medicine in Bologna, Italy.

Ms. Zinzani is highly rated in 36 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, T-Cell Lymphoma, Bone Marrow Transplant, and Splenectomy.

She is actively involved in clinical research, co-authoring 539 peer reviewed articles and participating in 29 clinical trials.

Gender

Female

Locations

Bologna, Italy

Other Locations

Trieste, Italy

Rome, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

29 Clinical Trials

ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients With Castleman Disease

Enrollment Status: Recruiting

Publish Date: March 03, 2026

Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Ibrutinib in Combination to Rituximab-CHOP Followed by Ibrutinib Maintenance in Untreated Patients With Activated-B-Cell (ABC)-DLBCL at Intermediate-high and High Risk (IPI ≥2)

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2026

Intervention Type: Drug

Study Drug: Ibrutinib

Study Phase: Phase 2

A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression

Enrollment Status: Completed

Publish Date: August 13, 2026

Intervention Type: Drug

Study Drugs: Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone

Study Phase: Phase 2

A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Enrollment Status: Active_not_recruiting

Publish Date: July 22, 2026

Intervention Type: Drug, Other

Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide

Study Phase: Phase 3

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)

Enrollment Status: Active_not_recruiting

Publish Date: July 02, 2026

Intervention Type: Drug

Study Drugs: Selinexor, Rituximab, Gemcitabine, Dexamethasone, Cisplatin

Study Phase: Phase 2/Phase 3

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Enrollment Status: Active_not_recruiting

Publish Date: July 02, 2026

Intervention Type: Drug

Study Drug: Selinexor

Study Phase: Phase 2

Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study by the Fondazione Italiana Linfomi.

Enrollment Status: Completed

Publish Date: June 01, 2026

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)

Enrollment Status: Active_not_recruiting

Publish Date: May 15, 2026

Intervention Type: Drug

Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib

Study Phase: Phase 3

Novel Immuno-epigenetic Based Platform for Patients With Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL): an International Phase Ib Study of Pembrolizumab Combined With Decitabine and/or Pralatrexate

Enrollment Status: Active_not_recruiting

Publish Date: April 07, 2026

Intervention Type: Drug

Study Drugs: Pembrolizumab, Pralatrexate, Decitabine

Study Phase: Phase 1

An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma

Enrollment Status: Completed

Publish Date: February 18, 2026

Intervention Type: Drug

Study Drugs: Zanubrutinib, Obinutuzumab

Study Phase: Phase 2

View 9 Less Clinical Trials

539 Total Publications

Correction to: Modern and multidisciplinary care in polycythemia vera.

Journal: Annals of hematology

Published: July 25, 2026

View All 539 Publications

Frequently Asked Questions about Pier L. Zinzani

Is Pier L. Zinzani a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Pier L. Zinzani is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Pier L. Zinzani participate in research or clinical trials?

Yes. Pier L. Zinzani has published 539 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Pier L. Zinzani's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Zinzani's expertise for a condition

ConditionClose